AIM: To compare the effects of additional educational material on treatment satisfaction of overactive bladder (OAB) patients treated with a muscarinic receptor antagonist.
METHODS: In an observational study of OAB patients being treated by their physician with fesoterodine for 4 months (FAKTEN study), sites were randomised to providing standard treatment or additional educational material including the SAGA tool. Patient satisfaction was assessed by three validated patient-reported outcomes including the Treatment Satisfaction Question. Because of premature discontinuation of the study, descriptive statistical analysis was performed.
RESULTS: A total of 431 and 342 patients received standard treatment or additional educational material, respectively. At study end, 76.1% (95% CI = 71.3, 80.4) of patients with standard care and 79.6% (95% CI = 74.4, 84.1) with additional SAGA tool were satisfied with treatment (primary end-point). Comparable outcomes with and without the additional educational material were also found in various patient subgroups, at the 1-month time point, and for the other patient-reported outcomes. A notable exception was the subgroup of treatment-naïve patients in which the percentage of satisfied patients was 77.2% vs. 89.5% with standard treatment and additional SAGA tool, respectively (post hoc analysis).
DISCUSSION AND CONCLUSIONS: In an observational study, most overactive bladder patients were satisfied with fesoterodine treatment. Because of the small sample size, the study does not support or refute the hypothesis that adding the SAGA tool will improve patient satisfaction with treatment. The potential effect of additional educational material in treatment-naïve patients warrants further dedicated studies.
Written by:
Schneider T, Arumi D, Crook TJ, Sun F, Michel MC. Are you the author?
Praxisklinik Urologie Rhein-Ruhr, Mülheim, Germany.
Reference: Int J Clin Pract. 2014 May 5. Epub ahead of print.
doi: 10.1111/ijcp.12450
PubMed Abstract
PMID: 24797765
UroToday.com Overactive Bladder (OAB) Section
